CLINICAL STUDY

Autoantibodies from patients with autoimmune thyroid disease do not interfere with the activity of the human iodide symporter gene stably transfected in CHO cells

Massimo Tonacchera, Patrizia Agretti, Giovanni Ceccarini, Rosanna Lenza, Samuel Refetoff¹, Ferruccio Santini, Aldo Pinchera, Luca Chiovato and Paolo Vitti

Dipartimento di Endocrinologia e Metabolismo, Ortopedia e Traumatologia, Medicina del Lavoro, Università di Pisa, Pisa, Italy and

¹Department of Medicine, Department of Pediatrics and the JP Kennedy Jr Mental Retardation Research Center, The University of Chicago, Chicago, Illinois, USA

(Correspondence should be addressed to M Tonacchera, Dipartimento di Endocrinologia, Università degli Studi di Pisa, Via Paradisa 2, 56124, Cisanello, Pisa, Italy; Email: mtonacchera@hotmail.com)

Abstract

Objective: The human sodium iodide symporter (hNIS) is a candidate autoantigen in autoimmune thyroid diseases. To investigate the possible existence of autoantibodies able to interfere with the biological activity of hNIS, an assay was developed using a cell line stably expressing hNIS.

Methods: hNIS complementary cDNA cloned in pcDNA3 and a neomycin resistance gene vector were co-transfected into CHO cells. After selection with geneticin, a cell line termed PA₄, showing the highest level of Na¹²⁵I uptake, was characterized. The time course of iodide uptake was evaluated by incubating PA₄ cells with 10 µmol/l NaI and 0.1 µCi Na¹²⁵I for a period up to 90 min. The accumulation of iodide increased linearly between 2 and 10 min, reaching a plateau at 45 min. The curve of iodide efflux mirrored that of iodide influx. Both perchlorate and thiocyanate inhibited iodide uptake in PA₄ cells in a dose-dependent manner starting from concentrations as low as 0.01 and 0.1 µmol/l respectively and complete inhibition was obtained at concentrations of 100 µmol/l perchlorate and 1000 µmol/l thiocyanate. The sensitivity of the inhibition assay was further improved using both inhibitors after 5 min incubation and in the absence of cold NaI.

Results: Included in the study were 42 patients with Graves' disease (25 had active hyperthyroidism, ten were euthyroid and seven had hypothyroidism); 34 patients with Hashimoto's thyroiditis (one was euthyroid, four had subclinical hypothyroidism and 29 were overtly hypothyroid); and 19 with atrophic thyroiditis (all hypothyroid).

Four out of eight whole sera from patients with Hashimoto's thyroiditis, and 8 out of 25 whole sera from patients with Graves' disease caused an inhibition of iodide uptake in PA₄ cells greater than 20% but also in 4 out of 15 sera from normal subjects. This inhibition activity exerted by sera from patients and controls was lost after dialyzing against buffer. Accordingly, IgGs purified from sera of all patients with Graves' disease and with Hashimoto's thyroiditis or atrophic thyroiditis were devoid of any effect on iodide uptake.

Conclusions: In conclusion, we believe that autoantibodies able to block the function of hNIS are very rare.

European Journal of Endocrinology 144 611–618

Introduction

Autoimmune thyroid diseases (ATD) are organ-specific autoimmune disorders (1) characterized by the presence in the patient's sera of autoantibodies to thyroid-specific proteins such as thyroglobulin (Tg), thyroperoxidase (TPO) and the thyrotropin receptor (TSHr) (1). Tg and TPO antibodies are used as clinical markers of ATD, while TSHr antibodies may either stimulate thyroid adenylate cyclase causing hyperthyroidism (TSAb) (1) or block thyroid function producing hypothyroidism (1–3).

Recently, the sodium iodide symporter (NIS) has been cloned and sequenced in the rat (4), leading to the sequencing of the human NIS (hNIS) (5). NIS, a membrane-bound glycoprotein located at the basolateral portion of the thyroid follicular cell (6), is responsible for active accumulation of iodide within the thyroid gland, a critical step in the biosynthesis of thyroid hormones (6). The protein is composed of 13 membrane-spanning segments separated by 14 extramembranous domains (6). NIS has been proposed as another candidate autoantigen in ATD (7–12) and it has been hypothesized that antibodies to hNIS may

produce a biological effect by inhibiting iodide uptake in thyroid follicular cells. Serum from a single patient with Hashimoto's thyroiditis (HT) inhibited iodide uptake in dog thyrocyte cultures (7). IgGs from patients with Graves' disease (GD), and more rarely from patients with HT, have been shown to bind recombinant rat NIS peptides in an ELISA assay (8). Furthermore, a few IgGs from HT patients inhibited iodide uptake in a Chinese Hamster Ovary (CHO) cell line stably expressing the rat NIS (9). Recently, Ajjan *et al.* (11) showed that 31% of sera from patients with GD inhibited iodide uptake in a CHO cell line stably expressing the hNIS protein. Purified IgGs from six of these GD patients also inhibited iodide uptake to a variable degree (11). The same authors described also that 22% of GD and 24% of HT sera reacted with the *in vitro*-translated unglycosylated ^{35}S hNIS protein (12). Three out of the seven sera of HT patients and 8 of the 11 sera of GD patients positive in the hNIS binding assay also inhibited iodide uptake in the bioassay using CHO cells stably expressing hNIS (12). Using a stable COS cell line expressing high levels of functional hNIS, a low prevalence of iodide uptake inhibiting activities after testing 299 sera from patients with ATD was observed by Ho *et al.* (13). The inhibitory activity was abolished after dialysis of the sera and could not be reproduced using purified IgGs.

In the present paper we report the establishment of a new cell line stably transfected with hNIS and studied the activity of putative autoantibodies directed against this protein. This cell line expressed the functioning hNIS and was inhibited by both perchlorate and thiocyanate in a dose-dependent manner. Sera and IgGs from patients with GD and HT were tested to search for autoantibodies able to inhibit iodine uptake but no such activity was found.

Patients

GD

Diagnosis of GD was based on common clinical criteria which included hyperthyroidism as assessed by elevated serum thyroid hormone levels, undetectable TSH and high ^{131}I thyroid uptake. At palpation, echography and scintiscan a diffuse enlargement of the thyroid gland was observed. In 30 patients a hypoechogenic pattern at ultrasonography was described. In 16 patients ophthalmopathy was clinically evident. Sera were obtained from 42 patients. Most had high levels of Tg antibodies (TgAb) and TPO antibodies (TPOAb) and 18 patients had TSH receptor antibodies (TSHrAb). Twenty-five out of the 42 patients had active hyperthyroidism, 10 were euthyroid (under medical treatment with methimazole) and seven had hypothyroidism (after ^{131}I therapy or under medical treatment with methimazole).

HT and atrophic thyroiditis

The diagnosis of HT was based on the evidence of a typical goiter associated with high titers of circulating TgAb and TPOAb. Atrophic thyroiditis (AT) was diagnosed in patients with primary hypothyroidism and circulating TPOAb and TgAb associated with a non-palpable gland. Hypothyroidism was defined by the presence of increased serum levels of TSH with free thyroxine (FT_4) and free tri-iodothyronine (FT_3) in the normal range (subclinical) or reduced (overt hypothyroidism). Goiter size was estimated by palpation and ultrasonography. A typical hypoechogenic pattern was demonstrated in all patients by ultrasonography. Fifty-three patients with HT or AT were included in the study. Among the 34 patients with HT, one was euthyroid (HT-E), four had subclinical hypothyroidism (HT-SH) and 29 had overt hypothyroidism (HT-H). The remaining 19 patients had AT with hypothyroidism. Eleven out of 28 patients with HT-H and 8 of 14 patients with AT had TSH binding inhibiting antibodies.

Thyroid radioiodine uptake at 24 h (normal range 30–50%) was determined in most patients (23 of 29 with HT-H and 12 of 19 with AT). Fifteen patients with HT-H showed a low iodide uptake, seven a normal uptake, while one showed an elevated uptake. All 12 patients with AT showed a low iodide uptake.

Sera were obtained before treatment in all patients with HT-E and HT-SH, while one patient with HT-H and three with AT had been receiving L-thyroxine for few months when the blood sample was obtained.

Healthy controls

Sera were also obtained from 15 healthy controls in which tests for thyroid antibodies gave negative results.

Materials and methods

Laboratory investigation

Serum FT_4 and FT_3 concentrations were measured by RIA after chromatographic separation of the free hormone (FT_4 RIA, FT_3 RIA, Lysophase; Technogenetics S.r.l., Milan, Italy). Serum TSH levels were determined by a sensitive assay (AutoDelfia hTSH Kit; Pharmacia s.p.a., Milan, Italy). TPOAb and TgAb were measured by passive agglutination (SERODIA-AMC and SERODIA-ATG, Fujirebio, Tokyo, Japan). TSHrAb were searched for using a commercial radioreceptor assay (TRAK assay; B.R.A.H.M.S., Berlin, Germany). Autoantibodies blocking the TSH-dependent production of cAMP in cell lines expressing the TSHr were measured using a previously described method (14).

IgG preparation

IgGs were prepared with a commercial kit according to the manufacturer's instructions (Mab Trap G II Pharmacia Biotech, Uppsala, Sweden)

Establishment of the CHO-K1 cell line expressing the hNIS

The hNIS complementary DNA (cDNA) cloned into the eukaryotic expression vector pcDNA3 and encoding amino acids 1 to 612 of hNIS was cloned as described by Pohlenz *et al.* (15).

The hNIS-pcDNA3 and a neomycin resistance gene vector (pSV2NEO) were co-transfected into CHO-K1 cells using a modified calcium phosphate method (16). Cells were plated out in 60 mm culture dishes and after 24 h were transfected with the two vectors. After 6 h incubation, cells were washed twice with Dulbecco Modified Eagle's Medium (DMEM) and fresh medium containing 10% fetal calf serum (FCS) was added. Selection was started 48 h after transfection by addition of medium containing 400 µg/ml geneticin (G418 from Gibco, Paisley, Scotland, UK). Medium was changed every day for about 3 weeks. When non-transfected cells in control dishes had all died, cells were trypsinized and subjected to screening, using the Na¹²⁵I uptake assay. The mixed CHO-K1 cell population was subjected to limiting dilution to produce individual clonal cell lines. Briefly, serial dilutions of the transfection product were seeded into 96-well micro-titer plates. Wells were screened the following day by inspection under the microscope and those containing only one cell were retained. Cells in these wells were allowed to grow to confluence, trypsinized and further amplified in 90 mm culture dishes.

Iodide uptake assay

One hundred thousand cells were plated in 24-well plates and cultured in DMEM containing 10% FCS. When cells reached 100% confluence, Na¹²⁵I uptake was determined by incubating cells at 37 °C for 45 min with 500 µl buffer A (Hanks' balanced salt solution (HBSS) containing 0.5% BSA and 10 mM HEPES, pH 7.4) containing 100 000 c.p.m. of carrier-free Na¹²⁵I (0.1 µCi) with or without NaI (5–625 µmol/l). After incubation, cells were quickly washed twice with 2 ml of ice-cold buffer A. Cells were then solubilized with 1 ml of 0.1 mol/l NaOH. The radioactivity from each well was counted using a γ-counter. Data of iodide uptake were expressed as pmol/well.

Iodide efflux

Iodide efflux from cells was measured as described by Weiss *et al.* (17). Cells were incubated with 10 µmol/l NaI and 100 000 c.p.m. Na¹²⁵I in 500 µl HBSS

incubation buffer at 37 °C for 60 min. Cells were then washed rapidly once with 2 ml HBSS incubation buffer, the medium was removed gently (in order not to dislodge the cells) and replaced with 500 µl fresh non-radioactive medium every 3 min. The medium was HBSS incubation buffer with 10 µmol/l NaI, which was kept at 37 °C. After the last medium removal, cells were solubilized for counting along with the previously collected medium samples. The total radioactivity present at the beginning of the efflux study (100%) was calculated by adding the final radioactivity measured in the cells to the radioactivity of the media collected at different time intervals. Data of iodide efflux were expressed as pmol/well.

Effect of sera and IgGs on NIS activity assessed by iodide uptake

To determine the effect of sera or IgGs from patients with ATD on hNIS activity, 250 µl buffer A containing 50 µl of serum (or serum previously dialyzed against TRIS buffer) or 1 mg/ml IgG was incubated with cells for 60 min at 37 °C. After this pre-incubation, 250 µl buffer A containing Na¹²⁵I (with and without 10 µmol/l NaI) was added and cells were further incubated for 5 min or 45 min, followed by washing and solubilization as above. All experiments were performed in triplicate cultures. Results were expressed as percent of Na¹²⁵I uptake measured in parallel cultures incubated without sera or IgGs.

Results

Isolation of CHO-K1 clones expressing the hNIS

To check hNIS function, iodide uptake studies were carried out on both the transfected CHO-K1 mixed cell population and the control (wild type CHO-K1 cells).

The uptake of Na¹²⁵I in the mixed cells was about 100-fold greater than the uptake of the control,

Figure 1 CHO cell clones expressing the hNIS obtained after transfection. Clone no. 4 showing the highest level of Na¹²⁵I uptake (PA₄) and clone PA₁₄ were used.

Figure 2 Time course of iodide accumulation in PA₄ after addition of Na¹²⁵I and iodide efflux from the same cells. The curve of iodide efflux was measured as described in Materials and methods. Results are the means of triplicate cultures $\pm$ S.E.S (S.E.S are so small that they fall within the symbols) and are expressed as pmol/well.

suggesting that a functioning NIS protein was present. Several cell clones were obtained and screened for iodide uptake (Fig. 1). A cell line termed PA₄ that showed the highest level of Na¹²⁵I uptake among all screened colonies (400-fold greater than the uptake of non-transfected CHO cells) was characterized and then used for further experiments.

Iodide kinetic characteristics of the PA₄ clone

The time course of iodide uptake was evaluated by incubating PA₄ cells with 10 μ M NaI for a period up to 90 min. The maximum Na¹²⁵I uptake of PA₄ cells, when plated in 24-well plates, was between 30 000 and 40 000 c.p.m./well. Non-transfected CHO cells had an uptake of 100 c.p.m./well.

The accumulation of iodide in PA₄ cells increased linearly between 2 and 10 min, reaching a plateau at 45 min (Fig. 2). The curve of iodide efflux measured after 60 min incubation mirrored that of iodide influx (Fig. 2), indicating that equilibrium was established with a velocity of iodide transport of 90 pmol/min per well in both directions. The velocity of iodide uptake increased with increasing concentrations of extracellular iodide following the Michaelis–Menten equation (Fig. 3). Fig. 3 also shows the kinetic parameters of iodide uptake, as examined by Lineweaver–Burk analysis. The value for K_m was 11.5 μ M and that of maximum velocity was 113 pmol/min per well. Both perchlorate and thiocyanate inhibited iodide uptake in PA₄ cells in a dose-dependent manner (Fig. 4a and b); when incubated for 45 min in the presence of 10 μ M NaI inhibition started from concentrations as low as 0.01 and 0.1 μ M respectively and complete inhibition was obtained at concentrations of 100 μ M perchlorate and 1000 μ M thiocyanate. Inhibition of iodide uptake was more evident at 5 min than at 45 min incubation (Table 1). The concentration producing 50% inhibition was 0.5 vs 2.8 μ M (5 min vs 45 min respectively) for perchlorate, and 6.2 vs 10.3 μ M (5 min vs 45 min respectively) for thiocyanate. To increase the sensitivity of the inhibition assay we tested both inhibitors in the presence of Na¹²⁵I with no cold NaI added. Under these conditions the lowest concentration of inhibitor that produced a significant inhibition of iodide uptake was 10 times lower for both perchlorate and thiocyanate (Table 1).

Effects of patients' sera and IgGs on iodide uptake

Effects of sera We started to study the effect of only eight whole sera from the 53 patients with HT and 25

Figure 3 Dependency of velocity of iodide uptake on the extracellular iodide concentration in PA₄ cells. Data are expressed as means of triplicate wells $\pm$ S.E.S (S.E.S are so small that they fall within the symbols). Inset: double reciprocal plot: $1/V$ expressed as $1/(\text{pmol/min per well})$ and $1/[S]$ as $1/\mu\text{M}$. All points of triplicate wells are plotted.

Figure 4 The effect of perchlorate (a) and thiocyanate (b) on iodide uptake by PA₄ cells 45 min after Na¹²⁵I addition. Results are the means of triplicate cultures ± S.E.S (S.E.S are so small that they fall within the symbols) and are expressed as pmol/well.

whole sera from the 42 patients with GD on Na¹²⁵I uptake activity of PA₄ cells. Four out of eight sera of patients with HT, and 8 out of 25 sera of patients with GD caused an inhibition of iodide uptake greater than 20% (Fig. 5). A similar inhibiting effect was produced

Table 1 The effect of perchlorate and thiocyanate on iodide uptake by PA₄ cells 5 min and 45 min after Na¹²⁵I addition. The 5-min incubation was performed in the presence (+) and in the absence (–) of 10 μM NaI. Results are expressed as % inhibition.

	% inhibition		
	45 min +	5 min +	5 min –
<i>Perchlorate (μmol/l)</i>			
0	0	0	0
0.001	0	0	5
0.01	3	11	8
0.1	7	22	19
1	40	76	73
10	82	95	96
100	97	99	98
<i>Thiocyanate (μmol/l)</i>			
0	0	0	0
0.01	0	0	15
0.1	1	14	19
1	12	29	28
10	48	71	60
100	83	93	92
1000	98	99	99

Figure 5 The inhibition of iodide uptake by normal sera, GD and HT or AT patients' sera. Results are the mean of triplicate cultures ± S.E.S (S.E.S are so small that they fall within the symbols) and are expressed as % of Na¹²⁵I uptake in parallel cultures incubated with buffer alone without sera.

by 4 out of 15 sera obtained from normal subjects. After dialyzing against the buffer, all these sera lost their inhibiting activity on iodide uptake (Fig. 6). After the results obtained with this first series of normal sera tested we decided to use directly purified IgGs for further experiments.

Effects of IgGs IgGs were prepared from 42 sera of patients with GD and 53 sera of patients with HT or AT. The iodide uptake inhibition assay was performed both in the presence of 10 μmol/l NaI and in its absence, after 5 and 45 min incubation. None of the IgGs was

Figure 6 The inhibition of iodide uptake by one normal serum, one serum from a GD patient and one serum from a HT patient after incubation with different dilutions of the sera (white columns) or different dilutions of sera after dialysis against buffer (stippled columns). Results are calculated as in Fig. 5.

Figure 7 The inhibition of iodide uptake by normal IgGs, GD and HT or AT patients' IgGs. Results are the mean of triplicate cultures $\pm$ S.E.S (S.E.S are so small that they fall within the symbols) and are expressed as % of Na^{125}I uptake in parallel cultures incubated with buffer alone without IgGs.

able to inhibit iodide uptake in the various experimental conditions (Fig. 7).

IgGs were also tested in the same experimental conditions (after 5 and 45 min incubation, both in the presence and in the absence of NaI) with another clone designated PA₁₄. This clone had an iodide uptake activity that was tenfold lower than PA₄ cells, the reduced iodide uptake of the PA₁₄ probably being due to a lower level of expression of a functioning hNIS protein on the cell surface. Again, none of these IgGs was able to inhibit iodide uptake in PA₁₄ cell line (data not shown).

Discussion

We established new cell lines stably expressing hNIS and used them to search for autoantibodies able to inhibit the iodide uptake. Given that thyroid-specific proteins such as Tg, TPO and the TSHr act as autoantigens in ATD (1), it is conceivable that hNIS could also act as an autoantigen. Differences in the structural characteristics and in the exposure to immunocompetent cells of these proteins might be responsible for a different ability to trigger autoimmunity. Tg is a glycosylated iodoprotein that accumulates in the follicular lumen of thyroid follicles and small amounts of this protein are detected in serum (1). TPO is a glycosylated hemoprotein mainly bound to the apical membrane of thyroid follicular cells (1). Both Tg and TPO are expressed on the surface of thyroid follicular cells. The TSH receptor is a membrane-bound protein with a large extracellular portion (18). NIS is a membrane-bound glycoprotein located at the basolateral portion of the thyroid follicular cell (6) with a very short extracellular domain. Patients with HT or AT often show a low radioiodine uptake (1–3), probably due to thyroid gland atrophy or by lymphocytic infiltration. On the other hand, the possibility of

autoantibodies inhibiting the Na^{125}I symporter activity has been hypothesized to have a role in reducing the iodide uptake in patients with hypothyroid ATD. However, it has been shown that the amounts of NIS mRNA and protein are increased in thyroid tissue from Graves' patients (19). It has also been demonstrated that the TSH/cAMP pathway up-regulates NIS gene expression and NIS protein abundance in thyroid follicular cells in primary culture (19). These data are in agreement with the elevated levels of ^{131}I uptake in patients with GD. It is commonly believed that the increased NIS expression in GD is due to increased cAMP accumulation induced by TSHr antibodies.

After cloning the rat NIS cDNA, Endo *et al.* (8) used the recombinant protein blotted on nitrocellulose sheets to detect antibodies against NIS in sera of patients with ATD. Eighty-four percent of sera from patients with GD and 15% of sera from patients with HT recognized the recombinant protein. The corresponding patient's IgGs also stained the recombinant NIS in Western blot (8). Morris *et al.* (10) reported that 24 out of 27 IgGs from patients with GD, 17 out of 27 IgGs from patients with HT and 7 out of 20 IgGs from normal subjects were able to bind to rat recombinant NIS peptides in an ELISA system. However, antibodies able to recognize linear epitopes may be devoid of a functional activity (1). One out of 144 sera from patients with HT inhibited iodide uptake in dog thyrocytes cultures (7). In another study, Endo *et al.* (9) showed that 4 out of 34 IgGs from patients with HT inhibited ^{125}I uptake in cells stably transfected with the rNIS (9). Two of these IgGs had a weak inhibitory activity (20% and 15%), while the other two IgGs gave a more pronounced inhibition of ^{125}I uptake ranging from 40 to 60% (9). Ajjan *et al.* (11) found that 30% of sera from patients with GD inhibited iodide uptake in CHO cells stably expressing hNIS protein. The inhibitory activity was also demonstrated using six IgGs. In a subsequent study (12) the same authors described that 22% of GD and 24% of HT sera reacted with the *in vitro*-translated unglycosylated ^{35}S [hNIS protein. Three of the seven sera from HT patients and 7 of 11 sera from GD patients which were positive in the hNIS binding assay also inhibited iodide uptake in the bioassay (12).

In the present study the potential biological effect of autoantibodies from patients with GD or HT on iodide transport was searched for using two new cell lines stably expressing a functioning hNIS protein. Our cell clone (PA₄) accumulated 400-fold more Na^{125}I than cells transfected with the vector alone. This uptake had a similar time course compared with cell clones expressing the rat NIS or FRTL-5 thyroid cells (20). Half-maximal levels were reached after 5–10 min and the plateau after 30 min. Similarly, the Na^{125}I uptake was inhibited by both perchlorate and thiocyanate in a dose-dependent manner. The curve of iodide efflux mirrored that of iodide influx, indicating that equilibrium was established with the same velocity of iodide

transport in both directions. All these features indicate that the PA₄ line expresses a functioning hNIS and can be used as a tool to detect thyroid autoantibodies that interfere with hNIS function.

When some sera from patients with HT or GD were tested, no stimulation of iodide uptake was found, while 50% of whole sera from patients with HT or AT and 32% of whole sera from patients with GD caused an inhibition of Na¹²⁵I uptake (Fig. 5). However, an inhibition was also produced by a few normal sera (Fig. 5). In keeping with previous results (9), sera from either ATD patients or controls lost their inhibitory activity on Na¹²⁵I uptake after dialyzing against the buffer (Fig. 6). This indicates that sera may contain dialyzable inhibitor(s) of NIS activity different from IgGs. Therefore, the use of purified IgGs is necessary to accurately evaluate the antibody activity.

We then tested purified IgGs from ATD patients following the experimental procedure reported in previous papers (11, 12, 17). None of our IgGs was able to interfere with iodide uptake. Our results are in contrast with the observation of Ajjan *et al.* (11). The discrepancy between our and previous studies is unlikely to be explained by differences in the kinetic characteristics of the stable cell lines expressing the NIS protein. Indeed, the time course of iodide uptake, and the iodide efflux properties of the two cell lines were similar. Both perchlorate and thiocyanate inhibited iodide uptake in the two cell lines, starting from concentrations as low as 0.01 and 0.1 µmol/l respectively. The 50% inhibition was between 0.1 and 1 µmol/l for perchlorate in the cell line described by Ajjan and 2.8 µmol/l in our bioassay. The concentration of thiocyanate producing a 50% inhibition of iodide uptake was similar in our cell line compared with that of Ajjan *et al.* (11). Furthermore, to increase the sensitivity of our assay we modified the experimental conditions by testing the inhibitors during the initial phase of iodide accumulation (when no significant efflux of iodide occurs) and in the absence of cold NaI (which reduces the uptake of Na¹²⁵I). Under these conditions both perchlorate and thiocyanate exhibited a greater inhibitory activity and lower concentrations of both inhibitors could be detected (Table 1). Even in these experimental conditions none of the IgGs from patients and controls were able to inhibit iodide uptake. The main difference between the two cell lines is that we used a stable cell line with a high iodide uptake with respect to the cell line used by the group of Ajjan *et al.* (11). Therefore we tested our IgGs using a cell clone (PA₁₄) having a lower iodide uptake. Also using these cells none of our IgGs inhibited iodide uptake. In another paper Ajjan *et al.* (12) established a new cell line with a higher iodide uptake. Using these cells the few IgGs tested from patients with HT and GD were able to inhibit iodide uptake (12). Only four IgGs out of 34 showed a relative potent inhibitory activity on iodide uptake by the cells

in the study of Endo *et al.* (9). In this paper the kinetic characteristics of the cell line are not described and only IgGs from patients with HT were used. Recently, using a stable COS cell line expressing high levels of functional NIS, a low prevalence of iodide uptake inhibiting activities after testing 299 sera from patients with ATD was observed by Ho *et al.* (13). The inhibitory activity was abolished after dialysis of the sera and could not be reproduced using purified IgGs. Besides, three anti-hNIS monoclonal antibodies were obtained by genetic immunization by Pohlenz *et al.* (21). None of these antibodies were able to inhibit iodide uptake by COS cells stably expressing hNIS. This last observation does not imply that other antibodies could not be able to interfere with NIS activity.

In conclusion, our results do not confirm previous studies reporting the occurrence of iodide uptake inhibitory IgGs in patients with ATD. This discrepancy can not be attributed to a lower sensitivity of our assay and we conclude that IgGs able to block the iodide transporter are very rare.

Acknowledgements

This work was supported by the following grants: Ministero dell'Università e della Ricerca Scientifica (MURST), Programma di Ricerca: Le malattie della tiroide: dalle basi molecolari alla clinica. MURST, Programma di Ricerca: Strategie per la valutazione degli effetti disruptivi dei contaminanti ambientali sul sistema endocrino degli animali e dell'uomo. CNR Progetto Biotecnologie CTB 99.00.224.PF 31: Basi molecolari delle neoplasie benigne e maligne della tiroide. DK 15.070 from the National Institute of Health, USA.

References

- 1 Davies TF. Causes of thyrotoxicosis: Graves' disease. In *The Thyroid: a Fundamental and Clinical Text*, edn 8, pp 518–531. Eds LE Braverman & RD Utiger. Philadelphia: Lippincott-Raven, 2000.
- 2 Konishi J, Jida Y, Endo K, Misaki T, Nohara Y, Matsuura N *et al.* Inhibition of thyrotropin-induced adenosine 3',5' monophosphate increase by immunoglobulins from patients with primary myxedema. *Journal of Clinical Endocrinology and Metabolism* 1983 **57** 544–549.
- 3 Chiovato L, Vitti P, Santini F, Lopez G, Mammoli C, Bassi P *et al.* Incidence of antibodies blocking thyrotropin effect *in vitro* in patients with euthyroid or hypothyroid autoimmune thyroiditis. *Journal of Clinical Endocrinology and Metabolism* 1990 **71** 40–45.
- 4 Dai G, Levy O & Carrasco N. Cloning and characterization of the thyroid iodide transporter. *Nature* 1996 **379** 458–460.
- 5 Smanik PA, Liu Q, Furminger K, Ryu K, Xing S, Mazzaferri EL *et al.* Cloning of the human sodium iodide symporter. *Biochemical and Biophysical Research Communications* 1996 **226** 339–345.
- 6 Levy O, Vieja A & Carrasco N. The Na⁺I⁻ symporter (NIS): recent advances. *Journal of Bioenergetics and Biomembranes* 1998 **30** 195–206.
- 7 Raspè E, Costagliola S, Ruf J, Mariotti S, Dumont JE & Ludgate M. Identification of Na⁺I⁻ cotransporter as a potential autoantigen

- in thyroid autoimmune disease. *European Journal of Endocrinology* 1995 **132** 399–405.
- 8 Endo T, Kogai T, Nakazato M, Saito T, Kaneshige M & Onaya T. Autoantibody against Na⁺I⁻ symporter in the sera of patients with autoimmune thyroid disease. *Biochemical and Biophysical Research Communications* 1996 **224** 92–95.
 - 9 Endo T, Kaneshige M, Nakazato M, Kogai T, Saito T & Onaya T. Autoantibody against thyroid iodide transporter in the sera from patients with Hashimoto's thyroiditis possesses iodide transport inhibitory activity. *Biochemical and Biophysical Research Communications* 1996 **228** 199–202.
 - 10 Morris JC, Bergert ER & Bryant WP. Binding of IgG from patients with autoimmune thyroid disease to rat sodium-iodide symporter peptides: evidence for the iodide transporter as an autoantigen. *Thyroid* 1997 **4** 527–534.
 - 11 Ajjan RA, Findlay C, Metcalfe RA, Watson PF, Crisp M & Ludgate M. The modulation of the human sodium iodide symporter activity by Graves' disease sera. *Journal of Clinical Endocrinology and Metabolism* 1998 **83** 1217–1221.
 - 12 Ajjan RA, Kemp H, Waterman EA, Watson PF, Endo T, Onaya T *et al.* Detection of binding and blocking autoantibodies to the human sodium-iodide symporter in patients with autoimmune thyroid disease. *Journal of Clinical Endocrinology and Metabolism* 2000 **85** 2020–2027.
 - 13 Ho SC, Khoo HC, Morgenthaler NG, Vassart G & Costagliola S. Rarity of anti-Na/I symporter (NIS) antibody with iodide uptake inhibiting activity in autoimmune thyroid diseases. *Journal of Clinical Endocrinology and Metabolism* 2000 **85** 3937–3940.
 - 14 Chiovato L, Vitti P, Bendinelli G, Santini F, Fiore E, Capaccioli A *et al.* Detection of antibodies blocking thyrotropin effect using Chinese hamster ovary cells transfected with the cloned human thyrotropin receptor. *Journal of Endocrinological Investigation* 1994 **17** 809–816.
 - 15 Pohlenz J, Rosenthal IM, Weiss R, Jhiang SM, Burant C & Refetoff S. Congenital hypothyroidism due to mutations in the sodium/iodide symporter. *Journal of Clinical Investigation* 1998 **101** 1028–1035.
 - 16 Perret J, Ludgate M, Libert F, Gerard C, Dumont JE, Vassart G *et al.* Stable expression of the human TSH receptor in CHO cells and characterization of differentially expressing clones. *Biochemical and Biophysical Research Communications* 1990 **171** 1044–1050.
 - 17 Weiss SJ, Philp NL & Grollman EF. Iodide transport in a continuous line of cultured cells from rat thyroid. *Endocrinology* 1984 **114** 1090–1098.
 - 18 Russo D, Arturi F, Chiefari E & Filetti S. Molecular insights into TSH receptor abnormality and thyroid disease. *Journal of Endocrinological Investigation* 1997 **20** 36–47.
 - 19 Saito T, Endo T, Kawaguchi A, Ikeda M, Nakazato M, Kogai T *et al.* Increased expression of the Na⁺I⁻ symporter in cultured human thyroid cells exposed to thyrotropin in Graves' thyroid tissue. *Journal of Clinical Endocrinology and Metabolism* 1997 **82** 3331–3336.
 - 20 Kosugi S, Sasaki N & Hai N. Establishment and characterization of a Chinese hamster ovary cell line, CHO-4J, stably expressing a number of Na⁺I⁻ symporters. *Biochemical and Biophysical Research Communications* 1996 **227** 94–101.
 - 21 Pohlenz J, Duprez L, Weiss RE, Vassart G, Refetoff S & Costagliola S. Failure of membrane targeting causes the functional defect of two mutant sodium iodide symporters. *Journal of Clinical Endocrinology and Metabolism* 2000 **85** 2366–2369.

Received 18 October 2000

Accepted 2 March 2001